SCHEMBL5301358

SCHEMBL5301358

Clc1ccc(CN2[C@@H]3CCC[C@H]2CC3)cc1Cl

nearest known ligand 0.53

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.53
POLB P06746 1/20 0.53
DRD2 P14416 1/20 0.52
DRD4 P21917 1/20 0.52
DRD3 P35462 1/20 0.52
SIGMAR1 Q99720 10/20 0.49
ARG1 P05089 1/20 0.45
ARG2 P78540 1/20 0.45
KMT2A Q03164 1/20 0.44
HRH3 Q9Y5N1 1/20 0.43
LMNA P02545 2/20 0.42
RAB9A P51151 2/20 0.42
NPC1 O15118 1/20 0.42
HTT P42858 1/20 0.42
MAPT P10636 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4036161 0.82 DRD2 (0.55) SMN1; SMN2POLBDRD2DRD4DRD3
SCHEMBL4036159 0.82 DRD2 (0.55) SMN1; SMN2POLBDRD2DRD4DRD3
SCHEMBL4039195 0.82 DRD2 (0.55) SMN1; SMN2POLBDRD2DRD4DRD3
SCHEMBL4034860 0.82 KMT2A (0.51) SMN1; SMN2POLBDRD2DRD4DRD3
SCHEMBL4037015 0.82 DRD2 (0.55) SMN1; SMN2POLBDRD2DRD4DRD3
SCHEMBL4037021 0.82 DRD2 (0.55) SMN1; SMN2POLBDRD2DRD4DRD3
SCHEMBL27676903 0.82 DRD2 (0.51) POLBDRD2DRD4DRD3SIGMAR1
SCHEMBL11097099 0.79 DRD2 (0.52) SMN1; SMN2POLBDRD2DRD4DRD3
SCHEMBL11094859 0.77 ARG1 (0.54) SMN1; SMN2DRD2DRD4DRD3SIGMAR1
SCHEMBL11094861 0.77 ARG1 (0.54) SMN1; SMN2DRD2DRD4DRD3SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1453511-A1 TROPANE DERIVATIVES HAVING DOPAMINE REUPTAKE INHIBITOR ACTIVITY FOR THE TREATMENT OF ISCHEMIC DISEASES NEUROSEARCH A/S (DK) 2004-09-08 EP claimed
WO-2003045388-A1 TROPANE DERIVATIVES HAVING DOPAMINE REUPTAKE INHIBITOR ACTIVITY FOR THE TREATMENT OF ISCHEMIC DISEASES NEUROSEARCH A/S (DK) 2003-06-05 WO claimed
WO-2007028770-A1 MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS FOR NEUROPROTECTION IN PATIENTS SUFFERING FROM AN ADVANCED STAGE OF A MENTAL DISEASE NEUROSEARCH A/S (DK) 2007-03-15 WO disclosed
WO-2007028769-A1 MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITOR FOR NEUROPROTECTION NEUROSEARCH A/S (DK) 2007-03-15 WO disclosed
EP-1755602-A1 MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITOR FOR THE INHIBITION OF BETA-AMYLOID (A BETA 40 AND A BETA 42) GENERATION NEUROSEARCH A/S (DK) 2007-02-28 EP disclosed
EP-1429811-A4 THEURAPEUTIC TROPANE COMPOUNDS HARVARD COLLEGE (US) 2006-05-17 EP disclosed
WO-2005117874-A1 MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITOR FOR THE INHIBITION OF BETA-AMYLOID (Aß40 AND Aß42) -GENERATION NEUROSEARCH A/S (DK) 2005-12-15 WO disclosed
EP-1429811-A1 THEURAPEUTIC TROPANE COMPOUNDS PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2004-06-23 EP disclosed
WO-2003015830-A1 THEURAPEUTIC TROPANE COMPOUNDS PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2003-02-27 WO disclosed
US-6395748-B2 Use treating Alzheimer's disease; monoamine reuptake inhibitor tropanes such as tesofensine (2-methoxymethyl-3-(3,4-dichlorophenyl)-tropane) NEUROSEARCH A/S (DK) 2002-05-28 US disclosed
US-6288079-B1 MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS; NERVOUS SYSTEM, PSYCHOLOGICAL, EATING, SLEEP, AND BRAIN DISORDERS; ALZHEIMER*S AND PARKINSON*S DISEASE; TESOFENSINE (2-ethoxymethyl-3-(3,4-dichlorophenyl)-tropane) NEUROSEARCH A/S (DK) 2001-09-11 US disclosed
EP-0885220-A1 TROPANE-DERIVATIVES, THEIR PREPARATION AND USE NEUROSEARCH A/S (DK) 1998-12-23 EP disclosed
WO-1997030997-A1 TROPANE-DERIVATIVES, THEIR PREPARATION AND USE NEUROSEARCH A/S (DK) 1997-08-28 WO disclosed